MedTrace Logo

Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes

NCT04816682 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-08-03

No results posted yet for this study

Summary

Of patients admitted to an internal medicine ward with internistic diagnosis/es together with COVID-19, substantial proportion has elevated liver enzymes. silymarin / silibinin (milk thistle extract) has been approved as an add-on therapy in various acute and chronic liver diseases; moreover, there is evidence to suggest that it's dual effect (anti-viral and immune-modulatory) might be of benefit in patients infected with SARS-CoV-2. As there is no effective/approved pharmacotherapy for COVID-19, a pilot study with Silymarine in hospitalised patients has been undertaken

Conditions

Interventions

DRUG

Silymarin

Silymarine tablets will be provided irrespective of meal by a registered nurse T.I.D

Sponsors & Collaborators

  • F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica

    lead OTHER

Principal Investigators

  • Lubomir SKLADANY, MD, PhD · Study Principal Investigator F.D.Roosevelt Teaching Hospital, Banska Bystrica, Slovakia

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-17
Primary Completion
2021-06-30
Completion
2021-12-30

Countries

  • Slovakia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04816682 on ClinicalTrials.gov